# Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

> **NCT01374425** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 376 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** 5-Fluorouracil
- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01374425
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2015-05
- **Final completion:** 2015-07
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2016-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374425, "Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01374425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*